Gene Therapy for Ophthalmic Disorders | August 5-6 - EDT | Online

Memo

More companies than ever before are realizing the potential of gene therapies to treat a wide range of ophthalmic disorders but in practice there are still hurdles to overcome. A variety of unique challenges must be addressed to effectively bring gene therapies to patients, from developing preclinical models that accurately translate to the clinic to validating clinical endpoints that will satisfy regulators. Gene Therapy for Ophthalmic Disorders will virtually unite industry leaders across the ophthalmology space to overcome the specific delivery and drug development challenges faced by companies developing gene therapies for ophthalmic diseases. Don't get left behind. Join pioneering companies including Novartis, Gensight Biologics and Spark Therapeutics to revolutionize the treatment of ophthalmic diseases. URLs: Brochure: https://go.evvnt.com/645519-1?pid=5569 Tickets: https://go.evvnt.com/645519-2?pid=5569  Date and Time: On Wednesday August 05, 2020 at 9:00 am ends Thursday August 06, 2020 at 5:30 pm Prices:2 Day Digital Conference - Standard: USD 1999.00,2 Day Digital Conference - Early Booking Rate: USD 1399.00 Speakers: Wiley Chambers, FDA, Thierry Bordet, Eyevensys, Dan Chung, Spark Therapeutics, Viral Kansara, Clearside Biomedical Inc., Brian Mansfield, Foundation for Fighting Blindness, Adam Rogers, Hemera Biosciences, Magali Taiel, Gensight Biologics, Abraham Scaria, IVERIC bio, Samantha Vieira, Biogen, Ashley Winslow, Odylia Therapeutics, Claire Gelfman, Adverum